You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Molecular features of responders to nivolumab

From: Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

  Assessed Detected Responder Non-responder ORR P-value
HER2+ 71 16 (23%) 1 15 6% 0.12
PD-L1+ in tumor cell 60 14 (23%) 8 6 57% < 0.01
CPS≥10 60 17 (28%) 6 11 35% 0.17
CPS≥1 60 54 (90%) 14 40 26% 0.15
EBV+ 68 4 (6%) 1 3 25% 0.82
MMR-D 68 8 (12%) 6 2 75% < 0.01
TMB≥10 54 32 (59%) 7 25 22% 0.44
ARID1A mutation 52 5 (10%) 1 4 25% 0.96
ERBB2 mutation 52 2 (4%) 0 2 0% 0.48
KRAS mutation 52 4 (8%) 0 4 0% 0.31
MET mutation 52 2 (4%) 0 2 0% 0.48
PIK3CA mutation 52 9 (17%) 4 5 44% 0.03
TP53 mutation 52 28 (54%) 6 22 21% 0.66
CCNE1 amplification 52 7 (13%) 2 5 29% 0.50
ERBB2 amplification 52 9 (17%) 0 9 0% 0.11
FGFR amplification 52 3 (6%) 0 3 0% 0.38
MDM2 amplification 52 2 (4%) 0 2 0% 0.48
MYC amplification 52 3 (6%) 0 3 0% 0.38
  1. CPS combined positive score, EBV Epstein-Barr virus, MMR-D mismatch repair deficient, ORR objective response rate, PD-L1 programmed cell death-1 ligand-1, TMB tumor mutation burden